Article

The therapeutic journey of benzimidazoles: A review.

Molecular Modelling Lab (MML), Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab 147002, India.
Bioorganic & medicinal chemistry (Impact Factor: 2.82). 09/2012; 20(21):6208-36. DOI: 10.1016/j.bmc.2012.09.013
Source: PubMed

ABSTRACT Presence of benzimidazole nucleus in numerous categories of therapeutic agents such as antimicrobials, antivirals, antiparasites, anticancer, anti-inflammatory, antioxidants, proton pump inhibitors, antihypertensives, anticoagulants, immunomodulators, hormone modulators, CNS stimulants as well as depressants, lipid level modulators, antidiabetics, etc. has made it an indispensable anchor for development of new therapeutic agents. Varied substitutents around the benzimidazole nucleus have provided a wide spectrum of biological activities. Importance of this nucleus in some activities like, Angiotensin I (AT(1)) receptor antagonism and proton-pump inhibition is reviewed separately in literature. Even some very short reviews on biological importance of this nucleus are also known in literature. However, owing to fast development of new drugs possessing benzimidazole nucleus many research reports are generated in short span of time. So, there is a need to couple the latest information with the earlier information to understand the current status of benzimidazole nucleus in medicinal chemistry research. In the present review, various derivatives of benzimidazole with different pharmacological activities are described on the basis of substitution pattern around the nucleus with an aim to help medicinal chemists for developing an SAR on benzimidazole derived compounds for each activity. This discussion will further help in the development of novel benzimidazole compounds.

0 Bookmarks
 · 
202 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prolyl hydroxylase 3 (PHD3) controls hypoxia-inducible factor-1 (HIF-1) degradation by oxygen dependent hydroxylation. PHD3 inhibitors are potential targets for HIF-1α activation, thereby treating a number of HIF-related diseases. We herein rationally designed a novel scaffold for PHD3 inactivation under the guidance of enzyme-ligand docking simulation studies. The potent inhibitors were able to non-covalently bind to the active site of PHD3, and to stabilize the core domain resisting to trypsin proteolysis. The conformational changes of the protein occurred concomitant with inhibitor binding, which thus deactivated the enzyme. The up-regulated levels of HIF-1α protein and downstream genes (glucose transporter-1 (GLUT-1) and vascular endothelial growth factor (VEGF)) suggest that the PHD inhibitors manage to mimic the cellular signalling effects of hypoxia. Interestingly, unlike available PHD inhibitors, the iron-chelating motif is not found in all azole compounds, among which we identified a unique compound 1-(2-(1H-benzo[d]imidazol-2-yl)ethyl)-1H-benzo[d][1,2,3]triazole (BEBT) as the most effective inhibitor. BEBT binds to the enzyme with the lowest predicted binding energy, and activates HIF activity most significantly in cellular systems. This novel non-iron-chelating inhibitor offers a new target for the drug design towards hypoxia-related diseases therapy with possibly minimized iron-relating side effects.
    Medicinal Chemistry Communication 01/2013; 4(9):1222. · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ligands 2-pyridin-2-yl-1H-benzimidazole (HL(1)), 1-methyl-2-pyridin-2-ylbenzimidazole (HL(2)), and 2-(1H-imidazol-2-yl)pyridine (HL(3)) and the proligand 2-phenyl-1H-benzimidazole (HL(4)) have been used to prepare five different types of new ruthenium(II) arene compounds: (i) monocationic complexes with the general formula [(η(6)-arene)RuCl(κ(2)-N,N-HL)]Y [HL = HL(1), HL(2), or HL(3); Y = Cl or BF4; arene = 2-phenoxyethanol (phoxet), benzene (bz), or p-cymene (p-cym)]; (ii) dicationic aqua complexes of the formula [(η(6)-arene)Ru(OH2)(κ(2)-N,N-HL(1))](Y)2 (Y = Cl or TfO; arene = phoxet, bz, or p-cym); (iii) the nucleobase derivative [(η(6)-arene)Ru(9-MeG)(κ(2)-N,N-HL(1))](PF6)2 (9-MeG = 9-methylguanine); (iv) neutral complexes consistent with the formulation [(η(6)-arene)RuCl(κ(2)-N,N-L(1))] (arene = bz or p-cym); (v) the neutral cyclometalated complex [(η(6)-p-cym)RuCl(κ(2)-N,C-L(4))]. The cytototoxic activity of the new ruthenium(II) arene compounds has been evaluated in several cell lines (MCR-5, MCF-7, A2780, and A2780cis) in order to establish structure-activity relationships. Three of the compounds with the general formula [(η(6)-arene)RuCl(κ(2)-N,N-HL(1))]Cl differing in the arene moiety have been studied in depth in terms of thermodynamic dissociation constants, aquation kinetic constants, and DNA binding measurements. The biologically most active compound is the p-cym derivative, which strongly destabilizes the DNA double helix, whereas those with bz and phoxet have only a small effect on the stability of the DNA double helix. Moreover, the inhibitory activity of several compounds toward CDK1 has also been evaluated. The DNA binding ability of some of the studied compounds and their CDK1 inhibitory effect suggest a multitarget mechanism for their biological activity.
    Inorganic Chemistry 10/2014; · 4.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A series of new N-alkyl-2-(3-methyl-indolyl)benzimidazoles 8(a–c) were synthesized by the condensation of N-alkyl-2-propylbenzimidazole-phenylhydrazone derivatives 7(a–c), in polyphosphoric acid (PPA) underwent cyclization via Fischer-indole synthesis. Alkylation of 8(b–c) with different alkylating agents gave the title compounds 9(a–f). All the synthesized compounds were characterized by spectral data. The newly synthesized compounds 8(a–c) and 9(a–f) which possess a variety of N-substituents in both benzimidazole and indole moieties, were evaluated for their antimicrobial and anticancer activities. The results showed that compounds 9b, 9c, and 9d were active only against Gram-positive bacteria, and selective antibacterial activity was exhibited by compounds 8c and 8e against Staphylococcus aureus MLS-16 and Bacillus subtilis, respectively. Further, compounds 8a, 8b, 8c, 9a, 9e, and 9f showed significant anti-proliferative activity.
    Medicinal Chemistry Research 03/2014; 23(9):3970-3978. · 1.61 Impact Factor